Toxicity Management for Emerging Bispecifics in Patients With RRMM
September 28th 2023Ajai Chari, MD, discusses managing toxicities in patients with relapsed/refractory multiple myeloma treated with emerging bispecific therapies, emphasizing common adverse events including cytokine release syndrome, target-related toxicities such as neutropenia, and mitigation strategies such as pre-medication, early intervention with tocilizumab, and dose modulation.
Watch
Petrylak Reviews Results From KEYNOTE-921 in mCRPC
September 28th 2023Daniel P. Petrylak, MD, discusses background and findings from the phase 3 KEYNOTE-921 study of pembrolizumab plus docetaxel vs placebo plus docetaxel in patients with metastatic castration-resistant prostate cancer who had received prior next-generation hormonal agent therapy.
Watch
Emerging Treatments for Patients With RRMM: Data From CARTITUDE-1
September 28th 2023Dr Ajai Chari highlights the CARTITUDE-1 study for its impressive results in the treatment of patients with relapsed/refractory multiple myeloma, noting a high response rate after three-year updates, which led to the accelerated approval of cilta-cel therapy.
Watch
Talquetamab in Patients With RRMM: Key Takeaways From MontumenTAL-1
September 28th 2023Ajai Chari, MD, details the accelerated FDA approval of talquetamab based on data from the MonumenTAL-1 study showing positive response rates in patients with advanced multiple myeloma. The study highlighted the latest efficacy results of every-two-week dosing, which demonstrated an advantageous option for patients treated with four or more lines of therapy and triple class exposure.
Watch
Case Presentation: A 71-Year-Old Woman with Relapsed/Refractory Multiple Myeloma (RRMM)
September 28th 2023Ajai Chari, MD, presents the case of a 71-year-old woman with relapsed/refractory multiple myeloma who showed signs of disease progression after four lines of therapy and was initiated on a recently FDA-approved bispecific antibody, talquetamab.
Watch
Closing Thoughts on Data Updates From IASLC 2023 World Conference on Lung Cancer
September 21st 2023Following their review of data from the IASLC 2023 World Conference on Lung Cancer with expert Stephen Liu, MD, Oncology Brothers Rohit Gosain, MD, and Rahul Gosain, MD, highlight key takeaways and future directions in care.
Watch
Data From FLAURA2: Osimertinib With or Without Chemotherapy in Metastatic NSCLC
September 21st 2023Expert Stephen Liu, MD, joins the Oncology Brothers to share insight into updated data from the FLAURA2 trial of osimertinib with or without chemotherapy in patients with metastatic non–small cell lung cancer.
Watch
Future Directions in Urothelial Cancer Treatment: Clinical Trials and Novel Agents
September 21st 2023Arlene Siefker-Radtke, MD, highlights the ongoing quest for improved treatment options in metastatic urothelial cancer, emphasizing the role of clinical trials and novel agents in addressing unmet needs.
Watch
Second-Line Strategies in Metastatic Urothelial Cancer: Balancing Options and Risks
September 21st 2023Arlene Siefker-Radtke, MD, delves into the complexities of managing progressive disease in metastatic urothelial cancer, outlining considerations for immune checkpoint inhibitors, antibody drug conjugates, and other targeted therapies.
Watch
Frontline Options for Metastatic Urothelial Cancer: Tailoring Treatment Choices
September 21st 2023Diverse approaches to frontline treatment for metastatic urothelial cancer, including eligibility for cisplatin-based chemotherapy, alternative regimens, and the impact of drug shortages on treatment decisions.
Watch